|Bid||7.50 x 1300|
|Ask||0.00 x 800|
|Day's Range||8.21 - 8.21|
|52 Week Range||5.96 - 12.16|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2012 Richard Chin was appointed CEO of Kindred Biosciences, Inc. (NASDAQ:KIN). First, this article will compare CEO...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine has approved Zimeta™ (dipyrone injection) for the control of pyrexia in horses.
Kindred Bio (KIN) delivered earnings and revenue surprises of -11.43% and -28.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
While Kindred Biosciences, Inc. (NASDAQ:KIN) shareholders are probably generally happy, the stock hasn't had...
Kindred Bio (KIN) delivered earnings and revenue surprises of -2.78% and -37.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
The biotech sector continues to have a very good week, although some profit taking did take place in the second half of trading Thursday even as the S&P 500 hit an all-time high. On Wednesday we considered a couple mid-cap biotech names that would make logical buyout candidates should we see an uptick in merger-and-acquisition (M&A) activity in the second half of the year. Kindred has just one approved product but several in development.
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Burlingame, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $515,000 in the period. Kindred Bio shares have dropped 18% ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Kindred Biosciences, Inc. (NASDAQ:KIN) have power over the company...
Kindred Biosciences, Inc. (NASDAQ:KIN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
KindredBio is a company focused on bringing ground-breaking human products and innovative new technologies to veterinary medicine. Yahoo Finance's Adam Shapiro and Brian Sozzi discuss with company founder & CEO, Richard Chin, along with its founder and president, Denise Bevers.